Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 2,803 Cr.
- Current Price ₹ 1,636
- High / Low ₹ 1,666 / 454
- Stock P/E 52.9
- Book Value ₹ 196
- Dividend Yield 0.01 %
- ROCE 21.3 %
- ROE 15.6 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 97.8 to 53.2 days.
Cons
- Stock is trading at 8.37 times its book value
- Promoter holding has decreased over last quarter: -0.95%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
(S): Standalone figures, shown where consolidated figures are not available.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 454 | 635 | 870 | |
| Sales growth | +19% | +67% | +34% | +5% | +63% | +16% | +19% | +66% | +24% | +27% | +40% | ||
| 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 545 | 740 | |
| Operating Profit | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 52 | 91 | 130 |
| OPM % | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 10% | 11% | 12% | 14% | 15% |
| 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 4 | 0 | |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 39 | 42 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 5 | 8 | 12 |
| Profit before tax | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 27 | 47 | 75 |
| Tax % | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | 27% | 28% | 31% | |
| 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 20 | 33 | 53 | |
| EPS in Rs | 0.37 | 1.51 | 2.01 | 1.70 | 3.72 | 1.58 | 1.68 | 4.77 | 7.95 | 11.08 | 13.90 | 19.89 | 32.03 |
| Dividend Payout % | 0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% | 2% | 2% | 1% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 61% |
| 5 Years: | 60% |
| 3 Years: | 78% |
| 1 Year: | 158% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 17 |
| Reserves | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 | 273 | 314 |
| 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 167 | 222 | 253 | |
| 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 | 142 | 190 | |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 | 774 |
| 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 | 118 | 153 | |
| CWIP | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
| 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 | 522 | 619 | |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 | 774 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 | -17 | 12 | |
| -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | -8 | -6 | -74 | |
| 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | 6 | 27 | 121 | |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 | 4 | 60 |
| Free Cash Flow | -1 | -3 | -3 | 9 | -4 | -12 | -1 | -7 | -24 | -8 | -23 | -62 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 108% | 85% | 117% | 303% | 8% | -128% | 2% | -17% | -52% | -1% | -32% | 13% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 | 68 | 142 | 53 |
| Inventory Days | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 | 246 | 267 | 219 |
| Days Payable | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 | 88 | 161 | 71 |
| Cash Conversion Cycle | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 205 | 225 | 248 | 201 |
| Working Capital Days | -54 | -44 | -39 | 42 | 66 | 65 | 116 | 126 | 97 | 92 | 76 | 78 |
| ROCE % | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 18% | 17% | 21% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Capsules Capacity millions per day ・Standalone data |
|
||||||||
| Granulation Capacity kgs per day ・Standalone data |
|||||||||
| Tablet Compression Capacity millions per day ・Standalone data |
|||||||||
| Countries with Product Registration / Export Presence countries ・Standalone data |
|||||||||
| Cumulative Registered Products (Final Registrations) products ・Standalone data |
|||||||||
| Products Under Registration (Pipeline) products ・Standalone data |
|||||||||
| Contract / Third-Party Manufacturing Locations locations ・Standalone data |
|||||||||
| Total SKUs (Stock Keeping Units) SKUs ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 and H1 FY27 earnings conference call released on 16 November 2026.
-
Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Dated 14.11.2026
- Board noted the Monitoring Agency Report for quarter ended September 30, 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- CARE report dated Nov. 13, 2026 flags 10-25% deviation in Rs 153.25 crore preferential issue proceeds.
-
Statement Of Deviation Or Variation For The Quarter Ended September 30, 2026.
- Fredun Pharmaceuticals reports no deviation in use of ₹128.78 crore preferential issue proceeds for quarter ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Nov 2026REC
-
Aug 2026Transcript REC
-
Jun 2026Transcript REC
-
Feb 2026Transcript
-
Nov 2025Transcript REC
-
Aug 2025Transcript REC
-
Jun 2025PPT
-
Jun 2025PPT
-
Feb 2023PPT
-
Jun 2019PPT
Business Overview:{# https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ad9e590-baf1-43e5-a921-d0d5a2e4d356.pdf#page=2#}
The company is a diversified healthcare company engaged in pharmaceuticals, nutraceuticals, cosmeceuticals, dietary supplements, and animal healthcare products. Its pharmaceutical portfolio spans multiple therapeutic areas, including antihypertensives, antidiabetics, antiretrovirals (ARVs), and narcotics.